» Articles » PMID: 3546183

Activity of Flavone Acetic Acid (NSC-347512) Against Solid Tumors of Mice

Overview
Publisher Springer
Specialty Oncology
Date 1986 Jan 1
PMID 3546183
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Flavone acetic acid (FAA) is a new antitumor agent that has recently entered Phase I clinical trials. In preclinical studies, we have found that FAA was broadly active against a variety of transplantable solid tumors of mice (colon #51, #07, #10, #26; pancreatic ductal adenocarcinomas #02 and #03; mammary adenocarcinoma #16/C/Adr; M5076 reticulum cell sarcoma and Glasgow's osteosarcoma). FAA was curative for colon adenocarcinoma #10 and pancreatic ductal adenocarcinoma #03. Thus, for the first time an agent has been identified with very broad, perhaps nearly universal solid tumor activity. FAA was also found to be orally active and stable in solution at 37 degrees C for 48 h. FAA was selectively cytotoxic in vitro for solid tumors over leukemias L1210 and P388 (in a soft-agar colony formation assay), thus correlating cellular selectivity in vitro with in vivo antitumor activity. The finding that FAA was active in vitro, established that the agent did not need metabolism (activation) outside the tumor cell. The main drawback of FAA was an unusual 'threshold' behavior in which only a narrow range of doses were active and splitting the dose markedly decreased activity.

Citing Articles

Identification and induction of cytochrome P450s involved in the metabolism of flavone-8-acetic acid in mice.

Pham M, Rhinn H, Auzeil N, Regazzetti A, Harami D, Scherman D Drug Metab Lett. 2011; 5(2):73-84.

PMID: 21457135 PMC: 3743746. DOI: 10.2174/187231211795305221.


Editorial: One small molecule: a new way to treat the flu?.

Young H J Leukoc Biol. 2011; 89(3):327-8.

PMID: 21357247 PMC: 3040466. DOI: 10.1189/jlb.1010580.


Labeling of oxidizable proteins with a photoactivatable analog of the antitumor agent DMXAA: evidence for redox signaling in its mode of action.

Brauer R, Wang L, Woon S, Bridewell D, Henare K, Malinger D Neoplasia. 2010; 12(9):755-65.

PMID: 20824052 PMC: 2933696. DOI: 10.1593/neo.10636.


Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5'6-dimethylxanthenone-4-acetic acid (Vadimezan).

Cheng G, Sun J, Fridlender Z, Wang L, Ching L, Albelda S J Biol Chem. 2010; 285(14):10553-62.

PMID: 20118240 PMC: 2856263. DOI: 10.1074/jbc.M109.065631.


Vascular disrupting agents in clinical development.

Hinnen P, Eskens F Br J Cancer. 2007; 96(8):1159-65.

PMID: 17375046 PMC: 2360146. DOI: 10.1038/sj.bjc.6603694.


References
1.
Venditti J, Wesley R, Plowman J . Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions. Adv Pharmacol Chemother. 1984; 20:1-20. DOI: 10.1016/s1054-3589(08)60263-x. View

2.
Corbett T, Roberts B, Leopold W, Peckham J, WILKOFF L, Griswold Jr D . Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res. 1984; 44(2):717-26. View

3.
Alberts D, Salmon S, Chen H, MOON T, Young L, Surwit E . Pharmacologic studies of anticancer drugs with the human tumor stem cell assay. Cancer Chemother Pharmacol. 1981; 6(3):253-64. DOI: 10.1007/BF00256978. View

4.
Edelstein M, Valeriote F, VIETTI T . Cellular quantitation of in vivo effects of 1-beta-D-arabinofuranosylcytosine on leukemia L1210. J Natl Cancer Inst. 1977; 58(4):941-7. DOI: 10.1093/jnci/58.4.941. View

5.
Hart I, Talmadge J, Fidler I . Metastatic behavior of a murine reticulum cell sarcoma exhibiting organ-specific growth. Cancer Res. 1981; 41(4):1281-7. View